Aurinia Pharmaceuticals (AUPH) Total Liabilities (2016 - 2026)

Aurinia Pharmaceuticals' Total Liabilities history runs 11 years deep, the most recent figure standing at $156.4 million for Q1 2026.

• Quarterly Total Liabilities rose 1.11% year-over-year to $156.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.4 million (up 1.11% YoY) and the FY2025 annual result came in at $170.3 million, down 1.68% from the prior year.
• Total Liabilities was $156.4 million for Q1 2026 at Aurinia Pharmaceuticals, down from $170.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $173.2 million in Q4 2024 and bottomed at $58.4 million in Q2 2022.
• A 5-year average of $132.9 million and a median of $157.2 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities soared 168.26% — and 2025, when it fell 1.68%.
• Aurinia Pharmaceuticals' Total Liabilities stood at $65.4 million in 2022, then soared by 160.0% to $170.1 million in 2023, then rose by 1.8% to $173.2 million in 2024, then fell by 1.68% to $170.3 million in 2025, then decreased by 8.16% to $156.4 million in 2026.
• Business Quant data shows AUPH's Total Liabilities at $156.4 million in Q1 2026, $170.3 million in Q4 2025, and $161.8 million in Q3 2025.